Nature Medicine asks leading researchers to name their most anticipated clinical trial for 2022, from CRISPR and psilocybin to oncolytic viruses.
| Treatment | Condition or disease | Sponsor | Phase and size |
|---|---|---|---|
| Mosaic nanoparticle immunogen FluMos-v1 | Influenza | NIAID | Phase 1; 35 participants |
| ASOs | Huntington’s disease | Roche / Genentech | Phase 3; 791 participants |
| CRISPR-based gene therapy NTLA-2001 | Transthyretin amyloidosis | Regeneron / Intellia Therapeutics | Phase 1; 38 participants |
| Miltefosine and paromomycin | Visceral leishmaniasis (kala-azar) | Drugs for Neglected Diseases Initiative | Phase 3; 439 participants |
| Pridopidine | Huntington’s disease | Prilenia Therapeutics | Phase 2/3; up to 480 participants |
| AAV9 U7 snRNA gene therapy | Duchenne muscular dystrophy | Nationwide Children’s Hospital / Audentes Therapeutics | Phase 1/2a; 3 participants |
| Psilocybin | Treatment-resistant depression | COMPASS Pathways | Phase 2a; 231 participants |
| Oncolytic vaccinia virus ASP9801 | Advanced or metastatic solid tumors | Astellas | Phase 1; 105 participants |
| Monoclonal antibody nirsevimab | RSV | MedImmune / AstraZeneca | Phase 3, 3000 participants |
| Monoclonal antibody pembrolizumab | Triple negative breast cancer | National Cancer Institute | Phase 3; 1155 participants |
| Various | COVID-19 | TOGETHER Trial | Adaptive trial; various |